FindTrial
Sign In

A clinical trial to determine neuropsychiatric comorbidities and serum folate, cyanocobalamin levels in drug-resistant epilepsy.

Neuropsychiatric comorbidities and serum folate cyanocobalamin levels in persons with drug resistant epilepsy an observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/082480
Enrollment
68
Registered
2025-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

AIIMS, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age equal to 18 years and above. 2. Persons diagnosed with drug-resistant epilepsy on the basis of ILAE criteria. 3. Subjects willing to participate and provide written informed consent. 4. Subjects with basic understanding of Hindi or English.

Exclusion criteria

Exclusion criteria: 1. Alcohol consumption. 2. Pregnant and lactating women. 3. History of other chronic communicable or noncommunicable medical illness. 4. Patients diagnosed with other neurological/psychiatric conditions and are on treatment for the same.

Design outcomes

Primary

MeasureTime frame
1.MINI score 2.NDDI-E score 3.PHQ-9 score 4.GAD-7 score 5.Serum folate and cyanocobalamin levelsTimepoint: at baseline—

Secondary

MeasureTime frame
To assess the prevalence & extent of neuropsychiatric comorbiditiesTimepoint: At 80 weeks—

Countries

India

Contacts

Public ContactDr Swathi Kona

All India Institute of Medical Sciences, New Delhi

jatinderkatyal.aiims@gmail.com01126593282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026